Intellia Thera CS (NTLA)

$8.70 +0.03 (0.35%)
Market Cap 1.10B
Revenue (ttm) 57.88M
Net Income (ttm) -519.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -896.72%
Debt to Equity Ratio 0.00
Volume 6,821,855
Avg Vol 8,929,254
Day's Range N/A - N/A
Shares Out 115.83M
Stochastic %K 2%
Beta 2.44
Analysts Sell
Price Target $22.07

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
APman
APman Nov. 14 at 8:19 PM
$NTLA Management will talk to analysts before the public. They have a history of that.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 5:52 PM
Hedge Alert Live - Protect Your Portfolio Contract: $NTLA $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.10 - $0.10 Exit Price Target: $0.21 Profit Margin: +109% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 14 at 4:58 PM
$NTLA reentered ... . Built 20k shares to start
0 · Reply
quark_n_jaguar
quark_n_jaguar Nov. 14 at 4:23 PM
$NTLA Just catching up - on FDA's hold, is there more detail than "Intellia is investigating the safety incident and working with FDA on resolution"? From just the medical perspective, what does it take for Intellia to investigate, and how long will it take them for that? Does anyone know? Also, what should we look out for next? Some public report from Intellia on this? Or do we expect them to have some internal conversation with the FDA for a while?
0 · Reply
ntrifiro
ntrifiro Nov. 14 at 3:48 PM
$NTLA Am I wrong here? Currently the stock looks like its trading for the value of cash and properties. Nothing else. Is that a fair value? trying to work thru this...
0 · Reply
GoFrogs09
GoFrogs09 Nov. 14 at 3:47 PM
$NTLA let’s go, only need $18 🤣
0 · Reply
APman
APman Nov. 14 at 3:14 PM
$NTLA A very good read. But remember that this was written NTLA was $25. https://www.insideprecisionmedicine.com/topics/precision-medicine/reporters-notebook-is-intellias-patient-death-the-nail-in-the-coffin-for-cas9/
0 · Reply
APman
APman Nov. 14 at 2:18 PM
$NTLA Concern is how well they can mitigate the issues. I think its a combination of delivery and the gene itself. Combined with ATTR-CM having a population skewed towards being old. Hope the new FDA lets it continue with stricter guidelines - that is the best case scenario.
1 · Reply
ZacksResearch
ZacksResearch Nov. 14 at 2:16 PM
Can $NTLA actually pull off a 2026 comeback? The company’s dealing with FDA clinical holds on key ATTR studies, and with crucial HAE data expected in 2026, lonvo-z is shaping up to be the make-or-break catalyst here. Full breakdown here 👉 https://www.zacks.com/stock/news/2791165/can-ntla-stock-bounce-back-in-2026-after-recent-pipeline-setbacks?cid=sm-stocktwits-2-2791165-teaser-21137&ADID=SYND_STOCKTWITS_TWEET_2_2791165_TEASER_21137
0 · Reply
ZacksResearch
ZacksResearch Nov. 14 at 1:16 PM
$NTLA faces a rocky road ahead with its late-stage pipeline! 🚧 ⚠️ FDA clinical hold on MAGNITUDE and MAGNITUDE-2 studies for NTLA-2001 for ATTR-CM and ATTRv-PN due to liver enzyme concerns 🔍 Grade 4 liver enzyme elevations in under 1% of MAGNITUDE study patients 📉 Shares have plunged 25.6% YTD despite trading at a discount with a 1.24 P/B ratio, lower than the industry average of 3.65 Full analysis here 👉 https://www.zacks.com/stock/news/2791165/can-ntla-stock-bounce-back-in-2026-after-recent-pipeline-setbacks?cid=sm-stocktwits-2-2791165-body-21125&ADID=SYND_STOCKTWITS_TWEET_2_2791165_BODY_21125
0 · Reply
Latest News on NTLA
Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 10, 2025, 3:17 PM EST - 4 days ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 8, 2025, 5:13 PM EST - 5 days ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

Nov 7, 2025, 5:46 AM EST - 7 days ago

Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 29, 2025, 5:11 PM EDT - 16 days ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Oct 27, 2025, 11:17 AM EDT - 18 days ago

Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:38 AM EDT - 18 days ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Oct 27, 2025, 7:30 AM EDT - 18 days ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Oct 24, 2025, 8:15 AM EDT - 21 days ago

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:01 PM EDT - 6 weeks ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 1:57 PM EDT - 7 weeks ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 25, 2025, 9:52 AM EDT - 7 weeks ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Sep 19, 2025, 2:31 PM EDT - 2 months ago

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 18, 2025, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Why big players are pouring millions in THIS biotech stock

Sep 1, 2025, 8:43 AM EDT - 2 months ago

Why big players are pouring millions in THIS biotech stock

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 15, 2025, 12:24 PM EDT - 3 months ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:17 PM EDT - 3 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jul 18, 2025, 8:00 AM EDT - 4 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 5 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 29, 2025, 11:25 AM EDT - 6 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 6 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 6 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 1:57 PM EDT - 6 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 12, 2025, 9:07 AM EDT - 6 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:37 AM EDT - 6 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 6 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 7 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 7 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 7 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 10, 2025, 10:40 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 1:03 PM EDT - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Apr 3, 2025, 7:30 AM EDT - 8 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

APman
APman Nov. 14 at 8:19 PM
$NTLA Management will talk to analysts before the public. They have a history of that.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 5:52 PM
Hedge Alert Live - Protect Your Portfolio Contract: $NTLA $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.10 - $0.10 Exit Price Target: $0.21 Profit Margin: +109% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Elaine_Shrimp
Elaine_Shrimp Nov. 14 at 4:58 PM
$NTLA reentered ... . Built 20k shares to start
0 · Reply
quark_n_jaguar
quark_n_jaguar Nov. 14 at 4:23 PM
$NTLA Just catching up - on FDA's hold, is there more detail than "Intellia is investigating the safety incident and working with FDA on resolution"? From just the medical perspective, what does it take for Intellia to investigate, and how long will it take them for that? Does anyone know? Also, what should we look out for next? Some public report from Intellia on this? Or do we expect them to have some internal conversation with the FDA for a while?
0 · Reply
ntrifiro
ntrifiro Nov. 14 at 3:48 PM
$NTLA Am I wrong here? Currently the stock looks like its trading for the value of cash and properties. Nothing else. Is that a fair value? trying to work thru this...
0 · Reply
GoFrogs09
GoFrogs09 Nov. 14 at 3:47 PM
$NTLA let’s go, only need $18 🤣
0 · Reply
APman
APman Nov. 14 at 3:14 PM
$NTLA A very good read. But remember that this was written NTLA was $25. https://www.insideprecisionmedicine.com/topics/precision-medicine/reporters-notebook-is-intellias-patient-death-the-nail-in-the-coffin-for-cas9/
0 · Reply
APman
APman Nov. 14 at 2:18 PM
$NTLA Concern is how well they can mitigate the issues. I think its a combination of delivery and the gene itself. Combined with ATTR-CM having a population skewed towards being old. Hope the new FDA lets it continue with stricter guidelines - that is the best case scenario.
1 · Reply
ZacksResearch
ZacksResearch Nov. 14 at 2:16 PM
Can $NTLA actually pull off a 2026 comeback? The company’s dealing with FDA clinical holds on key ATTR studies, and with crucial HAE data expected in 2026, lonvo-z is shaping up to be the make-or-break catalyst here. Full breakdown here 👉 https://www.zacks.com/stock/news/2791165/can-ntla-stock-bounce-back-in-2026-after-recent-pipeline-setbacks?cid=sm-stocktwits-2-2791165-teaser-21137&ADID=SYND_STOCKTWITS_TWEET_2_2791165_TEASER_21137
0 · Reply
ZacksResearch
ZacksResearch Nov. 14 at 1:16 PM
$NTLA faces a rocky road ahead with its late-stage pipeline! 🚧 ⚠️ FDA clinical hold on MAGNITUDE and MAGNITUDE-2 studies for NTLA-2001 for ATTR-CM and ATTRv-PN due to liver enzyme concerns 🔍 Grade 4 liver enzyme elevations in under 1% of MAGNITUDE study patients 📉 Shares have plunged 25.6% YTD despite trading at a discount with a 1.24 P/B ratio, lower than the industry average of 3.65 Full analysis here 👉 https://www.zacks.com/stock/news/2791165/can-ntla-stock-bounce-back-in-2026-after-recent-pipeline-setbacks?cid=sm-stocktwits-2-2791165-body-21125&ADID=SYND_STOCKTWITS_TWEET_2_2791165_BODY_21125
0 · Reply
Newcar
Newcar Nov. 14 at 12:43 PM
$NTLA 6$ good entry point?
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 10:22 AM
💎 LiquidTheta® Live Actionable Trade Asset: $NTLA Contracts: $NTLA January 15, 2027 $10 Calls Scale in: $3.76- $4.60 Scale out: $14.63-$25.08 Profit Potential : 159% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:13 AM
Hedge Alert Live - Protect Your Portfolio Contract: $NTLA $7.50 Put · NOV 21, 2025 Exp Entry Price: $0.03 - $0.15 Exit Price Target: $0.07 Profit Margin: +134% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Steppinstone
Steppinstone Nov. 14 at 2:08 AM
$NTLA The current market cap for NTLA now has $0 value allocated for nex-z. The lonvo-z data for HAE which was recently reported was almost flawless and reps the current MC. This presumed apocalyptic scenario for nex-z which is already baked into the price is premature at this point.
1 · Reply
JazzPaw
JazzPaw Nov. 14 at 1:49 AM
$NTLA Baffling that anyone would buy puts to protect a price of $9 until April and pay $2.40 for it. I’ve been selling puts on this stock when it gets hammered. As long as I still want to own it, I can’t see a downside with this IV.
0 · Reply
Rounderssss4
Rounderssss4 Nov. 14 at 1:20 AM
$NTLA Reporter’s Notebook: Is Intellia’s Patient Death the Nail in the Coffin for Cas9? | Inside Precision Medicine https://share.google/QuMztm5aJQUJ0Yqzn
0 · Reply
SqueezrGames
SqueezrGames Nov. 13 at 10:54 PM
$ASPI $XYZ $NTLA $NVA 6
0 · Reply
jeojackson
jeojackson Nov. 13 at 10:06 PM
$NTLA Everyone keeps saying the patient was 82. The median age for ATTR-CM participants is 78. Mitigation is the key, not selective participants.
1 · Reply
Steppinstone
Steppinstone Nov. 13 at 9:55 PM
$NTLA Patient‘s death is probably partially related to a pre existing gall bladder or pancreatic issue given the spike in bilirubin. Will be interesting to find out the causes. Still feel sorry for this patient in his 80’s.
0 · Reply
accretivewealth
accretivewealth Nov. 13 at 9:08 PM
$NTLA Smells like an equity wipe
0 · Reply
GoFrogs09
GoFrogs09 Nov. 13 at 9:07 PM
$NTLA What what a dumpster fire 🤣
0 · Reply
stu4
stu4 Nov. 13 at 8:22 PM
$NTLA CATHIE ..ATTENTION …hahaha She is soooooo, goood
1 · Reply